Tri-complex of Compound-23, KRAS G12C, and CypA

Tri-complex of Compound-23, KRAS G12C, and CypA Descriptor: (3R)-1-[(2E)-4-(dimethylamino)-4-methylpent-2-enoyl]-N-[(2S)-1-{[(1P,8R,10R,14S,21M)-22-ethyl-21-{2-[(1R)-1-methoxyethyl]pyridin-3-yl}-18,18-dimethyl-9,15-dioxo-16-oxa-10,22,28-triazapentacyclo[18.5.2.1~2,6~.1~10,14~.0~23,27~]nonacosa-1(25),2(29),3,5,20,23,26-heptaen-8-yl]amino}-3-methyl-1-oxobutan-2-yl]-N-methylpyrrolidine-3-carboxamide (non-preferred name), GTPase KRas, MAGNESIUM ION, ... Authors: Tomlinson, A.C.A, Knox, J.E, Yano, J.K. Deposit date: 2024-04-18 Release date: 2025-03-05 Last modified: 2025-04-09 Method: X-RAY DIFFRACTION (1.2 Å) Cite: Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers. J.Med.Chem., 68, 2025